Novartis AG
NVSEF- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001114448
No open-market purchases or sales by Novartis AG insiders were filed in the last 90 days; 2 institutions reported holding it in 13F filings for Q2 2026, worth $6.28M in total; no superinvestor holds it.
Other share classesNVS
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, 0 vs. previous quarter
- 2
- 13F valueReported value at the end of Q2 2026
- $6.28M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding NVSEF, Q2 2026
No superinvestor reported holding NVSEF at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Novartis AG insiders from Form 4, newest first.
No open-market purchases or sales by Novartis AG insiders are on file.
Top 10 13F holders, Q2 2026
The largest institutional positions in Novartis AG at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Partners Capital Investment Group, LLP | 24,335 | $3.81M | 0.13% | −3,879−13.7% | Reduced |
| Generali Investments CEE, investicni spolecnost, a.s. | 15,729 | $2.46M | 0.12% | −1,328−7.8% | Reduced |